Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : XP-102
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XP-102 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : XP-102
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abexinostat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma, Non-Hodgkin.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2019
Lead Product(s) : Abexinostat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abexinostat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 03, 2019
Lead Product(s) : Abexinostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abexinostat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Follicular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 02, 2019
Lead Product(s) : Abexinostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abexinostat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Details : Abexinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Follicular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2018
Lead Product(s) : Abexinostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pazopanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2018
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
